CMBA
MNPR icon

C.M. Bidwell & Associates’s Monopar Therapeutics MNPR Stock Holding History

C.M. Bidwell & Associates’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.7K Buy
+94
New +$5.82K ﹤0.01% 298

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

C.M. Bidwell & Associates's MNPR Position: Q2 2026 in Review

C.M. Bidwell & Associates opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 94 shares worth $8.7K. The stake represents ﹤0.01% of the portfolio and ranks #298 among its holdings.

96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • C.M. Bidwell & Associates held 94 shares of Monopar Therapeutics worth $8.7K as of Q2 2026.
  • Monopar Therapeutics was a new C.M. Bidwell & Associates position in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #298 holding.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.